Abstract 1267P
Background
Low dosage computer tomography (LDCT) is widely used to detect early-stage lung cancer, but concerns regarding accuracy and overdiagnosis persist. To enhance LDCT diagnosis using non-invasive molecular features, we developed a combinatorial model to distinguish between malignant and benign pulmonary nodules.
Methods
In a prospective cohort of 608 participants with pulmonary nodules, we performed targeted methylation sequencing and protein level measurement using Proximity Extension Assay. Radiomics features were extracted from LDCT images of 448 participants. A machine learning classifier, incorporating a transformer model and deep neuron network models, was trained and tested, by integrating molecular and image features.
Results
A total of 368 samples (184 benign and 184 malignant) with matched sex and age were randomly selected as the training set. The remaining 81 benign and 159 malignant samples were used as the test set. The methylation-only model had an AUC of 0.805 [95% CI 0.755-0.852], the protein-only model had an AUC of 0.816 [0.768-0.860], and the radiomics-only model achieved an AUC of 0.865 [0.812-0.912]. A combination of methylation and radiomics features generated an enhanced model with an AUC of 0.884 [0.840-0.927] (sensitivity = 0.824 [0.744-0.883], specificity = 0.772 [0.641-0.865]), outperforming models based on other combinations of two features. Integrating protein markers further improved the model (AUC = 0.895 [0.845-0.934]), with both sensitivity (0.849 [0.774-0.905]) and specificity (0.842 [0.721-0.918]) showing significant enhancements. The combinatorial model performed well across sample groups with different nodule sizes, particularly for samples with nodules no larger than 10 mm.
Conclusions
This study integrated DNA methylation, protein, and radiomics features to construct a robust combinatorial model with optimal performance, providing potential clinical utility for the management of pulmonary nodules.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
W. Li, Q. He, Y. Zhang: Financial Interests, Personal, Full or part-time Employment: Singlera Genomics Inc. Z. Su: Financial Interests, Personal, Full or part-time Employment: Singlera Genomics Ltd. R. Liu: Financial Interests, Personal, Officer: Singlera Genomics Inc. All other authors have declared no conflicts of interest.
Resources from the same session
1301P - A prognostic clinical and circulating biomarker model to identify futile chemo-radiotherapy (CRT) in stage III NSCLC
Presenter: Rianne Vaes
Session: Poster session 04
1302P - Treatment outcomes and safety of durvalumab following definitive chemoradiotherapy among patients with stage III NSCLC in Thai populations: A real-world, multi-center observational study
Presenter: Piyada Sitthideatphaiboon
Session: Poster session 04
1303P - Immune-modulating effects on tumor draining lymph nodes following neoadjuvant chemoradiotherapy combined with immunotherapy in patients with T3-4N0-1 NSCLC
Presenter: Ezgi Ulas
Session: Poster session 04
1304P - A structured multidisciplinary approach for diagnosing immune-related pneumonitis in patients undergoing adjuvant durvalumab for stage III non-small cell lung cancer
Presenter: Illaa Smesseim
Session: Poster session 04
1305P - Importance of the resected lung tumor specimen in patients with locally advanced and metastatic non-small cell lung cancer undergoing prior targeted therapy
Presenter: Jeong Uk Lim
Session: Poster session 04
1307P - The Biocartis Idylla GeneFusion Assay (RUO) for lung cancer testing: The experience of testing over 5000 tumours in routine practice
Presenter: Lee Robertson
Session: Poster session 04
1308P - Diameter threshold for lung nodules at low-dose CT screening: Chinese population screening experience
Presenter: YE WENJUN
Session: Poster session 04
1309P - Immune exhaustion in tumor-free lymph nodes of non-small cell lung cancer (NSCLC) patients is associated with performance status and survival
Presenter: Laura Sellmer
Session: Poster session 04
1310P - Loratadine: A potential game-changer in lung cancer treatment with improved survival outcomes
Presenter: Xiwen Liu
Session: Poster session 04
1311P - Understanding the basis for intrinsic resistance to KRASG12C inhibitors
Presenter: Alba Santos Ramos
Session: Poster session 04